{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Pre-existing ADA"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Treatment induced ADA"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Treatment boosted ADA"}],"denoms":[{"counts":[{"groupId":"OG000","value":"168"}],"units":"Participants"}],"description":"ADA were categorized as: pre-existing, treatment induced, and treatment boosted response. Pre-existing ADA was defined as ADA that were present in samples drawn during the pretreatment period (i.e., before the first isatuximab administration). Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA, including participants without pretreatment samples. Treatment boosted ADA was defined as pre-existing ADA with an increase in titer during the ADA on-study observation period.","groups":[{"description":"Participants received isatuximab 10 mg/kg, IV infusion on Days 1, 8, 15 and 22 in Cycle 1, and then on Days 1 and Day 15 of each 28-day treatment cycle plus carfilzomib 20 mg/m\\^2, IV on Days 1, and 2 in Cycle 1, and then escalated to 56 mg/m\\^2 on Days 8, 9, 15 and 16 of Cycle 1 and then on Days 1, 2, 8, 9, 15 and 16 of each subsequent 28-day treatment cycle and dexamethasone 20 mg, PO or IV on Day 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day treatment cycle until disease progression or unacceptable adverse event or participant's decision to discontinue the study treatment or any other reason, whichever comes first (maximum exposure: 111 weeks).","id":"OG000","title":"Isatuximab + Carfilzomib + Dexamethasone (IKd)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Analysis was performed on ADA evaluable population which included participants who received at least one dose of study drug from the IKd arm with at least one ADA assessment during the ADA on-study observation period with a reportable result. Data for this outcome measure was not planned to be collected and analyzed for Kd arm.","reportingStatus":"POSTED","timeFrame":"From first dose of study treatment up to 30 days after last dose of study treatment (maximum duration: 111 weeks)","title":"Number of Participants With Anti-Drug Antibodies (ADA): Primary Analysis","type":"SECONDARY","unitOfMeasure":"Participants"}